Literature DB >> 11602730

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

C E Parker1, L J Deterding, C Hager-Braun, J M Binley, N Schülke, H Katinger, J P Moore, K B Tomer.   

Abstract

Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS), in combination with proteolytic protection assays, has been used to identify the functional epitope on human immunodeficiency virus envelope glycoprotein gp41 for the broadly neutralizing anti-gp41 human monoclonal antibody 2F5. In this protection assay-based procedure, a soluble gp140 protein with a stabilizing intermolecular disulfide bond between the gp120 and gp41 subunits (SOS gp140) was affinity bound to immobilized 2F5 under physiological conditions. A combination of proteolytic enzymatic cleavages was then performed to remove unprotected residues. Residues of SOS gp140 protected by their binding to 2F5 were then identified based on their molecular weights as determined by direct MALDI-MS of the immobilized antibody beads. The epitope, NEQELLELDKWASLWN, determined by this MALDI-MS protection assay approach consists of 16 amino acid residues near the C terminus of gp41. It is significantly longer than the ELDKWA core epitope previously determined for 2F5 by peptide enzyme-linked immunosorbent assay. This new knowledge of the structure of the 2F5 epitope may facilitate the design of vaccine antigens intended to induce antibodies with the breadth and potency of action of the 2F5 monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602730      PMCID: PMC114670          DOI: 10.1128/JVI.75.22.10906-10911.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody.

Authors:  Y Xiao; Y Zhao; Y Lu; Y H Chen
Journal:  Immunol Invest       Date:  2000-02       Impact factor: 3.657

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.

Authors:  Y Xiao; M Liao; Y Lu; M P Dierich; Y H Chen
Journal:  Immunobiology       Date:  2000-01       Impact factor: 3.144

Review 4.  Epitope mapping by a combination of epitope excision and MALDI-MS.

Authors:  C E Parker; K B Tomer
Journal:  Methods Mol Biol       Date:  2000

Review 5.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

6.  Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.

Authors:  Y Xiao; X Dong; Y Chen
Journal:  Int Arch Allergy Immunol       Date:  2000-08       Impact factor: 2.749

7.  Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine.

Authors:  M Liao; Y Lu; Y Xiao; M P Dierich; Y Chen
Journal:  Peptides       Date:  2000-04       Impact factor: 3.750

8.  Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.

Authors:  Y Lu; Y Xiao; J Ding; M P Dierich; Y H Chen
Journal:  Scand J Immunol       Date:  2000-05       Impact factor: 3.487

9.  Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

Authors:  M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.

Authors:  M P D'Souza; D Livnat; J A Bradac; S H Bridges
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

View more
  65 in total

1.  Protein grafting of an HIV-1-inhibiting epitope.

Authors:  Samuel K Sia; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

2.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.

Authors:  Daniela Tudor; Huifeng Yu; Julien Maupetit; Anne-Sophie Drillet; Tahar Bouceba; Isabelle Schwartz-Cornil; Lucia Lopalco; Pierre Tuffery; Morgane Bomsel
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

4.  Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.

Authors:  Xueling Wu; Adam B Parast; Barbra A Richardson; Ruth Nduati; Grace John-Stewart; Dorothy Mbori-Ngacha; Stephanie M J Rainwater; Julie Overbaugh
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 7.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

8.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.